Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Go back to Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
(NASDAQ: KOD) Delayed: 87.72 -5.25 (5.65%)
Previous Close $92.97    52 Week High $ 
Open $91.14    52 Week Low $ 
Day High $94.64    P/E N/A 
Day Low $87.29    EPS $ 
Volume 943,039